Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer

We have evaluated the activity and safety of gefitinib, a small-molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in combination with docetaxel as first-line treatment of women with metastatic breast cancer (MBC). In total, 41 patients with MBC were enrolled in a first-line...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Ciardiello, F, Troiani, T, Caputo, F, De Laurentiis, M, Tortora, G, Palmieri, G, De Vita, F, Diadema, M R, Orditura, M, Colantuoni, G, Gridelli, C, Catalano, G, De Placido, S, Bianco, A R
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2006
Assuntos:
Clinical Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2361320/
https://ncbi.nlm.nih.gov/pubmed/16685276
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6603141
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados